Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology
Clinical Infectious Diseases · 17.11.2026
DOI: 10.1093/cid/ciag582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.11.2026. Verfasst von George R Thompson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity.
Methods
An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria.
Results
The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments.
Conclusions
The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA.
- Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA.
- University of California Davis Center for Valley Fever, Sacramento, California, USA.
- College of Medicine University of Arizona, Tucson, Arizona, USA.
- Division of Infectious Diseases and Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: George R Thompson, Neil M Ampel, Nathan C Bahr, Tom Chiller, Claudia E Frola, Nelesh P Govender, Thomas J Walsh, Emmanuel Roilides, Marisa H Miceli, Alessandro C Pasqualotto, Rob Purdie, Flavio Queiroz-Telles, Andrej Spec, Rosanne Sprute, Thuy Le, Ana Alastruey-Izquierdo
Zitieren
APA
Thompson, G. R., Ampel, N. M., Bahr, N. C., Chiller, T., Frola, C. E., Govender, N. P., Walsh, T. J., Roilides, E., Miceli, M. H., Pasqualotto, A. C., Purdie, R., Queiroz-Telles, F., Spec, A., Sprute, R., Le, T., & Alastruey-Izquierdo, A. (2026). Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag582
Vancouver
Thompson GR, Ampel NM, Bahr NC, Chiller T, Frola CE, Govender NP, et al. Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag582
BibTeX
@article{Thompson2026,
author = {Thompson, George R and Ampel, Neil M and Bahr, Nathan C and Chiller, Tom and Frola, Claudia E and Govender, Nelesh P and Walsh, Thomas J and Roilides, Emmanuel and Miceli, Marisa H and Pasqualotto, Alessandro C and Purdie, Rob and Queiroz-Telles, Flavio and Spec, Andrej and Sprute, Rosanne and Le, Thuy and Alastruey-Izquierdo, Ana},
title = {Trial Endpoints for Endemic Mycoses: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and European Confederation of Medical Mycology},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag582}
}
EUVIMED